Business Wire

Ncardia and Evotec Entered a Licencing Agreement for Disease Modelling Using iPS Cells

Jaa

Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809). The financial terms of the agreements are not disclosed.

Under the terms of the agreement, Evotec has broad access to Ncardia’s stem cell derived cellular disease modelling IP. The patent family encompasses the use of in vitro derived cells for testing drug efficacy, safety and target discovery.

Dr Stefan Braam, CEO Ncardia, commented: “Ncardia’s mission is to support and enable our clients to develop better medicines faster. The combination of iPSC derived disease models with phenotypic screening is an extremely powerful method to identify new drug candidates. This second license agreement in the course of two months validates Ncardia’s IP position and marks a further step in Ncardia technology strategy aimed at addressing the potential of stem cell applications in the drug discovery and development market."

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "In addition to our substantial internal efforts and collaborations, this agreement with Ncardia further strengthens Evotec’s position as a leading iPSC-based drug discovery platform.”

“This licensing agreement is consistent with our strategy to promote disease modelling as a validated approach for drug discovery and development and to offer access to this technology,” said Felix von Haniel VP sales and BD from Ncardia. “We are pleased to collaborate with Evotec, a well- established biotechnology partner, and pioneer in establishing stem cell derived disease models for drug discovery and development.”

About Ncardia:

Ncardia develops, produces and commercializes highly predictive human cellular assay systems for safety and efficacy testing. The product portfolio encompasses a broad panel of hiPSC derived cryopreserved cardiomyocytes and neurons. In addition, the company delivers the CardioPlateTM product line of quality controlled ready to use assay plates. Using its cell products, Ncardia develops and provides its customers with a broad portfolio of cardiovascular services from safety pharmacology and disease modeling to cardiovascular drug efficacy screening. Ncardia is based in Belgium, The Netherlands, Germany, and the USA. The company is privately held and was established in September 2017 following the merger of Pluriomics and Axiogenesis, two well-known pioneers in the field of stem cell derived cells for safety and toxicology assessment.

For more information please visit www.ncardia.com.

About Evotec:

Evotec is a drug discovery partnership company providing drug discovery solutions. With a large pool of highly experienced scientists, state-of-the-art technology platforms, first-class scientific operations and key therapeutic expertise in the areas of neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. Evotec drives research and development projects in numerous alliances and partnerships with Pharma and biotech companies as well as academia. The Company’s headquarters are located in Hamburg, Germany. Additional major operating sites exist in Europe and USA. Evotec has more than 2,000 employees worldwide. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.

For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.

Contact information

Ncardia
Felix von Haniel
VP BD & Sales
Felix.haniel@ncardia.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

SquareWell Partners Officially Launches Today to Assist Companies in Navigating the Evolving Demands of Investors25.9.2018 09:00Tiedote

SquareWell’s unique approach, supported by its proprietary technology, was developed out of the founding partners’ recognition of the need to optimize company-investor engagement practices and support proactive management of environmental, social and governance (ESG) risks for maximum impact. Over the last 15 years, the prominence of ESG issues has risen dramatically in the capital markets and knowing what investors prioritize and how best to communicate with them remains a challenge for companies. Furthermore, activism is no longer just an investment strategy but has become a mainstream behavior. SquareWell acknowledges this changing dynamic and facilitates progress by providing companies with year-round strategic advice regarding their investors. With SquareWell’s support, companies are better able to anticipate and identify risks and opportunities associated with long-term strategic issues, ranging from capital allocation to supply chain oversight. By analyzing existing data and lev

FRISS Survey Reveals Big Bang of Digital Transformation in Insurance is Yet to Come25.9.2018 08:30Tiedote

Today, FRISS, the worldwide provider of AI powered fraud and risk solutions for the P&C insurance industry, released the “Digital Transformation in Insurance Survey 2018”. The survey was initiated to get a better understanding of the current market state, uncovering emerging global trends in P&C insurance regarding digital transformation. Over 170 insurance professionals participated, from various countries across the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005072/en/ FRISS launches Digital Transformation in Insurance Survey 2018 Digital transformation provides the insurance industry with the opportunity to use technology in order to improve efficiency, customer satisfaction and realize new strategic opportunities. These opportunities could create new services or business models and improved efficiency. Digitalization also opens doors to improve customer experience. However, digitalization can also result

AMPLEXOR a Gold Plus Sponsor of the 2018 NORDIC TechKomm in Copenhagen25.9.2018 08:03Tiedote

AMPLEXOR, a top-10 global language solutions provider, is a Gold Plus Sponsor and presenter at this year’s NORDIC TechKomm in Copenhagen on 26–27 September. This two-day event brings together experts from all over Europe to share best practices and present current ideas on the main conference topic, "How to make your documentation intelligent today." NORDIC TechKomm is geared toward professionals in technical communication eager to learn and share their knowledge about the latest industry trends. Attendees can expect to learn about creating effective and engaging content, ensuring documentation teams are self-sustainable, understanding the importance of AI and technical communication and more. At the 2018 NORDIC TechKomm, AMPLEXOR’s Manager of Strategic Accounts and augmented reality (AR) expert, Gilberto Picareta, will present, “Augmented Reality and Technical Authoring.” The presentation will discuss how AR is impacting technical information and communication, how to incorporate and

Veezi Signs Deal with CanalOlympia, Vivendi's Pan African Cinema Network25.9.2018 08:00Tiedote

Vista Group International (NZX & ASX: VGL) company Vista Entertainment Solutions (‘Vista Cinema’) and Vivendi’s CanalOlympia have signed an agreement to roll-out Vista Cinema’s Veezi across all their cinema venues. Veezi, already utilised by cinemas in 27 countries, is Vista Cinema’s SaaS cinema management solution for Independent cinemas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924006098/en/ Currently operating 9 venues across 7 countries, CanalOlympia is the leading network of cinema and live performance venues in Africa. Several additional sites are set to open in the months to come, extending the breadth of the CanalOlympia footprint. The CanalOlympia operation showcases the diversity of African culture and has helped bring cinemas back to countries currently short on entertainment choices and cultural infrastructure. The venues include the latest projection and sound technologies. They produce their own electr

Panasonic's Multi-hop HD-PLC Adopted as Smart Meter Communications System by Taiwan Power Company25.9.2018 07:27Tiedote

Panasonic Corporation has successfully proposed adoption to Taiwan Power Company of its HD-PLC (*1) high-speed power line communications technology as a communications system to utilize next-generation smart meters. Taiwan Power Company began accepting proposals for technology relating to communications systems in June 2017. Verification testing of the latest wireless technology and power line communications technology was held in Taipei City in September of that year. Smart meters will be introduced to approx. 260,000 households in main cities of Taiwan from December 2018. The HD-PLC technology meets the high performance criteria required, and smart meters incorporating this technology will be introduced in Taipei and other areas. Smart meters require stable communications performance to achieve detailed controls matching power demand with high-frequency data collection. The HD-PLC technology can meet these requirements and is expected to contribute to building IoT communications infr

IFF Announces Pricing of $1,500,000,000 Senior Notes Offering25.9.2018 01:25Tiedote

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF), a leading innovator of sensorial experiences that move the world, today announced that it has priced its public offering of $300,000,000 aggregate principal amount of its 3.400% senior notes due 2020, $400,000,000 aggregate principal amount of its 4.450% senior notes due 2028 and $800,000,000 aggregate principal amount of its 5.000% senior notes due 2048. IFF intends to use the net proceeds from the offering to pay a portion of the consideration for the previously announced merger with Frutarom Industries Ltd. and to pay related fees and expenses. IFF anticipates that the offering will close on September 26, 2018, subject to customary closing conditions. The offering is not contingent upon the consummation of the merger. If the closing of the merger has not occurred on or prior to February 7, 2019, or, if prior to such date, the merger agreement with Frutarom is terminated, IFF will be required t

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme